AIM To detect the congenital expression patterns of mdr 1 gene in commonly encountered malignant tumors in clinic, and the relationship between the expression of mdr 1 gene and the prognostic morphology in ...AIM To detect the congenital expression patterns of mdr 1 gene in commonly encountered malignant tumors in clinic, and the relationship between the expression of mdr 1 gene and the prognostic morphology in esophageal carcinomas. METHODS A total of 151 resected samples of malignant tumors without preoperative treatment were taken from Anyang City Tumor Hospital. The congenital expression of their mdr 1 gene was detected with reverse transcription polymerase chain reaction (RT PCR) and was compared with each other. The positive incidence of mdr 1 gene in 46 samples of esophageal carcinoma was compared with their differentiated grades, TNM stages and macroscopic types, and the precautions and advantages of RT PCR were evaluated. RESULTS All the 151 samples were confirmed to be malignant histopathologically, including cancers of stomach and gastric cardia (n =51), esophagus ( n =46), colorectum ( n =16), breast ( n =15), thyroid ( n =10), lung ( n =9), uterine cervix ( n =24). The positive expression rate of their mdr 1 gene was 33 3%, 37%, 31 3%, 13 2%, 40%, 55%, and 0% respectively. All the 46 samples of esophageal carcinoma were pathologically confirmed to be squamous cell carcinoma. The total expression rate of their mdr 1 gene was 37% (17/46), 35% (6/17), 40% (8/20), and 33% (3/9) for differentiation grade Ⅰ, Ⅱ and Ⅲ respectively. The expression rate of TNM classification was 33% (6/18), 40% (5/12) and 37% (6/16) in stage Ⅱa, Ⅱb and Ⅲ. The expression rate was 33% (3/9) in ulcerous type, 37% (3/8) in constrictive one, 33% (5/15) in fungoid one, and 40% (6/14) in medullary one. No statistically significant difference was found. CONCLUSION Compared with other methods, RT PCR is more simple, reliable and accurate in detecting mdr 1 gene expression in tissues of tumor. The overexpression of mdr 1 gene in these neoplasms suggested that cases should be handled differently for chemotherapy with rational use of drugs. Excision is the chief tr展开更多
目的研究卵巢上皮性癌组织中多药耐药基因1、Surv iv in基因和拓扑异构酶Ⅱβ的表达及其临床意义。方法采用逆转录-聚合酶链反应检测66例卵巢上皮性癌、25例卵巢良性上皮性肿瘤、20例正常卵巢组织多药耐药基因1mRNA、Surv iv in mRNA和...目的研究卵巢上皮性癌组织中多药耐药基因1、Surv iv in基因和拓扑异构酶Ⅱβ的表达及其临床意义。方法采用逆转录-聚合酶链反应检测66例卵巢上皮性癌、25例卵巢良性上皮性肿瘤、20例正常卵巢组织多药耐药基因1mRNA、Surv iv in mRNA和拓扑异构酶ⅡβmRNA的表达。结果卵巢癌组织中多药耐药基因1mRNA、Surv iv in mRNA和拓扑异构酶ⅡβmRNA的阳性表达率分别为34.85%(23)、51.52%(34)及54.55%(36),正常卵巢组织及卵巢良性肿瘤多药耐药基因1mRNA表达均为阴性,拓扑异构酶ⅡβmRNA表达均为阳性,Surv iv in mRNA表达率分别为0及16%(4),卵巢良性肿瘤与上皮性癌相比存在显著性差异(P<0.01)。卵巢癌组织中多药耐药基因1mRNA阳性表达率与病理类型及期别无明显相关性(P>0.05),中、低分化组相比有显著性差异(P<0.05),高、低分化组有极显著差异(P<0.001);Surv iv in mRNA阳性表达率与病理类型有明显相关性(P<0.05),高、低分化组相比有显著性差异(P<0.01);拓扑异构酶ⅡβmRNA的阳性表达率与病理类型无明显相关性(P>0.05),与期别有明显相关性(P<0.05),高、低分化组相比存在显著差异(P<0.01)。结论检测多药耐药基因1、Surv iv in基因和拓扑异构酶Ⅱβ对卵巢癌化疗药物的选择具有指导意义,对预后判断有参考价值。展开更多
文摘AIM To detect the congenital expression patterns of mdr 1 gene in commonly encountered malignant tumors in clinic, and the relationship between the expression of mdr 1 gene and the prognostic morphology in esophageal carcinomas. METHODS A total of 151 resected samples of malignant tumors without preoperative treatment were taken from Anyang City Tumor Hospital. The congenital expression of their mdr 1 gene was detected with reverse transcription polymerase chain reaction (RT PCR) and was compared with each other. The positive incidence of mdr 1 gene in 46 samples of esophageal carcinoma was compared with their differentiated grades, TNM stages and macroscopic types, and the precautions and advantages of RT PCR were evaluated. RESULTS All the 151 samples were confirmed to be malignant histopathologically, including cancers of stomach and gastric cardia (n =51), esophagus ( n =46), colorectum ( n =16), breast ( n =15), thyroid ( n =10), lung ( n =9), uterine cervix ( n =24). The positive expression rate of their mdr 1 gene was 33 3%, 37%, 31 3%, 13 2%, 40%, 55%, and 0% respectively. All the 46 samples of esophageal carcinoma were pathologically confirmed to be squamous cell carcinoma. The total expression rate of their mdr 1 gene was 37% (17/46), 35% (6/17), 40% (8/20), and 33% (3/9) for differentiation grade Ⅰ, Ⅱ and Ⅲ respectively. The expression rate of TNM classification was 33% (6/18), 40% (5/12) and 37% (6/16) in stage Ⅱa, Ⅱb and Ⅲ. The expression rate was 33% (3/9) in ulcerous type, 37% (3/8) in constrictive one, 33% (5/15) in fungoid one, and 40% (6/14) in medullary one. No statistically significant difference was found. CONCLUSION Compared with other methods, RT PCR is more simple, reliable and accurate in detecting mdr 1 gene expression in tissues of tumor. The overexpression of mdr 1 gene in these neoplasms suggested that cases should be handled differently for chemotherapy with rational use of drugs. Excision is the chief tr
文摘目的研究卵巢上皮性癌组织中多药耐药基因1、Surv iv in基因和拓扑异构酶Ⅱβ的表达及其临床意义。方法采用逆转录-聚合酶链反应检测66例卵巢上皮性癌、25例卵巢良性上皮性肿瘤、20例正常卵巢组织多药耐药基因1mRNA、Surv iv in mRNA和拓扑异构酶ⅡβmRNA的表达。结果卵巢癌组织中多药耐药基因1mRNA、Surv iv in mRNA和拓扑异构酶ⅡβmRNA的阳性表达率分别为34.85%(23)、51.52%(34)及54.55%(36),正常卵巢组织及卵巢良性肿瘤多药耐药基因1mRNA表达均为阴性,拓扑异构酶ⅡβmRNA表达均为阳性,Surv iv in mRNA表达率分别为0及16%(4),卵巢良性肿瘤与上皮性癌相比存在显著性差异(P<0.01)。卵巢癌组织中多药耐药基因1mRNA阳性表达率与病理类型及期别无明显相关性(P>0.05),中、低分化组相比有显著性差异(P<0.05),高、低分化组有极显著差异(P<0.001);Surv iv in mRNA阳性表达率与病理类型有明显相关性(P<0.05),高、低分化组相比有显著性差异(P<0.01);拓扑异构酶ⅡβmRNA的阳性表达率与病理类型无明显相关性(P>0.05),与期别有明显相关性(P<0.05),高、低分化组相比存在显著差异(P<0.01)。结论检测多药耐药基因1、Surv iv in基因和拓扑异构酶Ⅱβ对卵巢癌化疗药物的选择具有指导意义,对预后判断有参考价值。
